ESR1 and breast carcinoma: Camizestrant (AZD9833), developed by AstraZeneca, demonstrated superior efficacy and tumor inhibition in patients with ER+/HER2− advanced breast cancer compared to fulvestrant in the Phase II SERENA-2 trial (NCT04214288) (241, 242, 362–365).